Introduction

Coronavirus disease is by far the largest pandemic of the century. Within a short span of 6 months, it has spread to over 200 countries of the world. Concomitantly, it has afflicted more than 100 million people across the globe and killed over 2.2 million people. Despite active and aggressive research across the globe, till now we do not have a possible cure for the COVID-19 infection. Pending multiple and robust randomized controlled studies, some drugs are being used globally based on in-vitro studies, in-vivo evidence, observational studies, and small nonrandomized studies. Remdesivir is a nucleotide analog. It inhibits viral RNA polymerase enzyme. Several studies have hitherto demonstrated the promising in-vitro and in-vivo antiviral activities of the molecule against severe acute respiratory syndrome coronavirus (SARS-CoV-1) and the Middle East respiratory syndrome coronavirus (MERS-CoV) strains. It has now exhibited potential in vitro activity against SARS-CoV-2 strains too. Based on pivotal studies, remdesivir is now being used to treat moderate to severe patients through emergency use authorizations and other access programs around the world. This review aims to summarize the evidence and clinical trials of remdesivir as a potential therapeutic option for COVID-19.

Methods

We systematically searched the PubMed and Clinical trials. org database up till January 25, 2021, using the several specific keywords “COVID 19” and “Remdesivir” or “SARS COV 2” etc. and retrieved all the articles published in the English language that reported efficacy, safety, clinical outcome, and pharmacology with the remdesivir in patients with COVID-19. We compiled all the data and narrated the past, present, and future of remdesivir in the context of COVID-19.

Coronavirus pandemic – An update

Coronaviruses are single-stranded RNA viruses belonging to the...
Coronaviridae family. The initial reports of the infection came from Wuhan, Hubei province, People’s Republic of China in late December 2019. After that, the virus has spread fast across the globe and was declared a pandemic by the WHO on the 10th of March 2020. Currently, the virus has spread across more than 190 countries involving up to 11 million people. The fatality from the virus has gone beyond 500,000 and in many countries, the case fatality ratio is more than 10%. But we are yet to have a potential cure for the infection. There are many potential candidates in the fray including chloroquine, hydroxychloroquine, ritonavir/lopinavir, plasma therapy, corticosteroids, and interleukin hormones. Many of these drugs have demonstrated antiviral activity previously and are hence being tried against this novel virus.

Remdesivir – The drug
Remdesivir (GS-5734™) is an experimental antiviral drug developed by Gilead Life Sciences. The drug is active primarily against RNA viruses and has proven prior efficacy against Ebola and MERS-CoV viruses. It is a nucleotide prodrug and after metabolism the active forms and becomes ATP analog. The active analog inhibits RNA-dependent RNA polymerase, inhibiting viral replication through premature termination of RNA transcription in a broad range of viruses including severe acute respiratory syndrome coronavirus (SARS-CoV). The drug has also shown in vitro activity against SARS-CoV-2 in airway epithelial cells. The safety of the drug was established in studies for Ebola virus treatment. The half-life of the drug is 20 h permitting a once-daily dosing. As the prodrug is hydrolyzed in the gastrointestinal tract, oral administration is precluded.

Remdesivir – The initial experience
A small study (n = 53) of compassionate use of the drug in severe COVID-19 had shown significant improvement in oxygen requirement and improved extubation rates on mechanical ventilation. This study had provided the basis for further studies on the drug. But, a subsequent study of 237 patients had failed to show clinical improvement compared to the placebo. However, patients with symptoms less than 10 days, showed clinical improvement with the drug. Serious adverse events (respiratory distress or failure), however, were higher in the study prompting trial discontinuation. The trial had also failed to meet its enrollment target and hence was underpowered. The results of the study can be best called inconclusive, and the results fueled the need for more data.

SIMPLE study
It was a phase 3 multicenter trial of the drug in 180 sites across the world. About 397 patients hospitalized with COVID-19 pneumonia were randomized to remdesivir with standard therapy (5 day and 10-day regimens) versus standard of care. A 7-point ordinal score was used to assess the improvement in clinical status which was the primary endpoint. Safety of the drug was the key secondary outcome. The patients who underwent the 5-day regimen were significantly more likely to have clinical improvement compared to the standard group (OR-1.56; P = 0.017) as were the patients in the 10-day arm, but results did not meet statistical significance (OR-1.31; P = 0.18). More than 75% of patients in the 5 day regimen had more 1 point improvement in the ordinal scale while 76% in the 10-day regimens had improvement. Compared to this in the standard care group, only 66% had some improvement in the ordinal scale. No significant side effects were observed during this study. Nausea, diarrhea, and headaches were seen in more than 5% of the study population. The study was funded by Gilead Life Sciences.

Adaptive COVID-19 Treatment Trial (ACTT-1) study
The study also endeavored to find the role of the drug in COVID-19 infection. About, 1063 patients hospitalized with COVID-19 respiratory infection were randomized to the drug or placebo. The time to recovery was significantly shortened in the remdesivir arm (11 days versus 15 days; P < 0.001). Mortality at 14 days (Kaplan Meier estimates) was significantly lower in the remdesivir arm (7.1% vs. 11.9%). Interestingly, adverse effects were not different from the placebo arms attesting to the safety of the drug. The study was principally funded by the National Institute of allergy and Infectious Diseases (NIAID) and the National Institute of Health (NIH) lending more credibility and free of commercial bias. Table I gives a brief of the three major trials of the drug.

ACTT1 trial final report showed that remdesivir is superior to placebo in hospitalized patients with COVID-19 pneumonia. It reduces the time to recovery. Remdesivir group had a shorter time to recovery than patients in the placebo group (median, 10 days, as compared with 15 days). It also prevents progression to more severe respiratory disease, lower evidence of severe adverse events, and lower incidence of oxygen use who were not on oxygen.

The National Institute of Allergy and Infectious Diseases (NIAID) has recently published data on the combination of baricitinib and remdesivir versus monotherapy with remdesivir in the ACTT-2 study (NCT04401579). ACTT-2 trial showed that baricitinib plus remdesivir is superior to remdesivir alone in patients with COVID-19 pneumonia those receiving high flow oxygen or noninvasive ventilation. The combination therapy reduces recovery time and showed improvement in clinical status. The drug was also a part of the international collaboration launched by the World Health Organization -WHO SOLIDARITY trial. The trial enrolled 11,330 patients from 30 countries and showed that remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had no benefit in overall mortality, initiation of ventilation, and duration of hospital stay in patients with COVID-19.

Drug Dosing
The drug is administered as an intravenous infusion. The loading
### Table 1: Pivotal trials of Remdesivir use in COVID-19 infection

| Author               | Study type                               | Patients type                                                                 | Drug dose                                                                 | Primary end points                                                                 | Outcome                                                                                           |
|----------------------|------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| ACCT1 Trial          | Double-blind, randomized, placebo-controlled trial \(n=1063\) | All in hospitalized patients \(n=541\) were assigned to the remdesivir group and \(n=522\) to the placebo group. | Remdesivir (200 mg loading dose on day 1 IV, followed by 100 mg daily for up to 9 additional days) | The time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. | Patients in the remdesivir group had a shorter time to recovery than patients in the placebo group (median, 11 days, as compared with 15 days; rate ratio for recovery, 1.32; 95% confidence interval [CI], 1.12 to 1.55; \(P<0.001\)); Remdesivir was not associated with a difference in time to clinical improvement (hazard ratio 1.23 [95% CI 0.87-1.75]), not statistically significant. However, remdesivir arm had a numerically faster time to clinical improvement than the placebo arm with a symptom duration of 10 days or less (hazard ratio 1.52 [9.95-2.43]) |
| Wang et al.          | Randomized, double-blind, placebo-controlled, multicenter trial \(n=237\) | All in hospitalized patients age \(>18\) y with oxygen saturation of 94% or lower on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and were within 12 days of symptom onset. | Intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions) | Time to clinical improvement up to day 28                                                                                     |                                                                                                    |
| SIMPLE trial         | Randomized, open-label, phase 3 trial \(n=397\) | Hospitalized patient's Age \(>12\) years, radiographic evidence of pulmonary infiltrates or had an oxygen saturation of 94% or less while they were breathing ambient air or were receiving supplemental oxygen. | All patients received 200 mg of and remdesivir on day 1 and 100 mg once daily on subsequent days. 5 days or 10 days regimen. | The primary endpoint was the clinical status on day 14, assessed on a 7-point ordinal scale. | 65% of patients who received a 5-day course of Remdesivir showed a clinical improvement of at least 2 points on the 7-point ordinal scale at day 14, as compared with 54% of patients who received a 10-day course. The two groups had similar outcomes after adjustment for baseline clinical status |
| Grein et al.         | Compassionate Use of remdesivir open-label program \(n=61\) | Hospitalized COVID-19 patients who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. | 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days | Although there were no pre specified endpoints for this program. However, quantified clinical events, including changes in oxygen-support, NIPPV, invasive mechanical ventilation, and ECMO, hospital discharge, and serious adverse events, and death were assessed. | 36 patients (68%) improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. |

IV = Intravenous; CI = confidence interval; NIPPV = noninvasive positive pressure ventilation, ECMO = extracorporeal membrane oxygenation

Dose is 200 mg on day 1, and it is followed by a maintenance dose of 100 mg daily for the rest of the days (4 days or 9 days). Other researchers have proposed additional intrapulmonary dosing to increase the therapeutic efficacy of the molecule.[16] The primary argument provided is the inadequate pulmonary levels attained by the drug to effectively neutralize the virus. The researchers calculate that assuming an 80% drug loss in the upper airways, a proposed dose of 50 mg administered via nebulization for 30 min could be one of the fastest methods of intrapulmonary delivery, and further investigation is needed for this potential route.

### Side Effect and Interaction Profile

Wang et al. demonstrated that rate of adverse events was almost similar in both the group (remdesivir vs placebo, 66% vs 64%).[14] Hypoalbuminemia, constipation, anemia, hypokalemia, increased aspartate aminotransferase, increased blood lipids, increased total bilirubin, nausea, and vomiting were common adverse effects in both the groups. Twenty-eight (18%) serious adverse events were reported in the remdesivir group and 20 (26%) were reported in the control group. Respiratory failure or acute respiratory distress syndrome was a serious adverse effect in the remdesivir group.

In more recent studies, common adverse events noted were increased hepatic enzymes, diarrhea, rash, renal impairment, and hypotension.[11,12] The most common serious adverse events were multiple organ dysfunction syndrome, septic shock, acute kidney injury, and hypotension. These side effects were more commonly seen in patients on invasive ventilation. The major contraindications are summarized in Figure 1.

Coadministration of remdesivir is not recommended with chloroquine or hydroxychloroquine by the United States Food and Drug Administration (FDA). Based on in vitro data, chloroquine...
demonstrated an antagonistic effect on the intracellular metabolic activation and antiviral activity of remdesivir.

**Remdesivir vis-à-vis Hydroxychloroquine**

**Economics and Beyond**

Gilead Life Sciences has priced remdesivir at $2,340 per patient for developed nations. Gilead will charge $3,120 per course, or $520 per vial for the U.S. patients with insurance, which is a 33% increase over the $390 per vial it will charge governments of developed countries and the U.S. patients in government health care programs. An analysis by the Institute of Clinical and Economic Review (ICER) has estimated that the drug becomes cost-effective at $460 per treatment course. The researchers used cost-effectiveness modeling and assumed 50,000 QALY gained with azithromycin. The drug was originally developed by an American firm Gilead and has been recently launched in India by generic drug makers such as Cipla, Hetero, and Mylan and priced, at less than 5,000 ($66) per 100 mg vial. Hydroxychloroquine (HCQS) is available freely across the globe at a price of less than $1 per tablet. Clinicians are also familiar with the use of the drug for the past 2 decades. However, the drug has not shown unequivocal benefits as shown by remdesivir in large randomized trials. Initial data was encouraging with small trials, but later larger trials failed to replicate these findings. But, because of low cost, good safety record, and widespread availability the drug is still on the recommendation of various guidelines. However, data has now emerged regarding the toxicity of the drug in combination with azithromycin – another combination that had initially positive reviews. Hence, HCQS should be used alone rather than in combination with azithromycin. Again, because of the corrected QT interval (QTc) interval prolonging behavior of HCQS, it is best avoided in patients with baseline QTc prolongation.

More recently, hydroxychloroquine has been removed from the World Health Organization’s phase III/IV SOLIDARITY trial for COVID-19. The trial initially planned for the evaluation of four investigational therapies that are lopinavir/ritonavir, remdesivir, and HCQS. Owing to the futility of HCQS in reducing mortality, the steering committee recommended discontinuation of the HCQS arm which the WHO has accepted.

Although not backed by rigorous clinical data, it would be safe to propose HCQS and remdesivir as complementary approaches in COVID-19. The former is best utilized in mild to moderate cases avoiding the cardiotoxic side effects in severe cases. Remdesivir is recommended in only moderate to severe cases as trials have generally included hospitalized patients only as the drug has to be administered intravenously and can have side effects which should be managed in an in-patient setting.

**Recommendations**

Remdesivir has been approved for emergency use in severely-ill patients in the United States, India, and South Korea. The drug is currently approved in Japan for the treatment of moderate to severe COVID-19. The United States Food and drug administration (USFDA) has also granted emergency use approval to the drug after the success of SIMPLE and ACTT-1 studies. The Drug Controlled General of India (DCGI) has also approved restricted emergency use of the drug for severely ill COVID-19 patients on the 1st of June. The key features of remdesivir are shown in Figure 2. The major guideline recommendations are summarized in Table 2.

**Future Directions**

Further trials of the drug are being conducted to evaluate the molecule in the management of COVID-19. Gilead Life Sciences is conducting another SIMPLE trial in patients with moderate COVID-19 disease (NCT04292730) and CARAVAN Study in children suffering from the disease (NCT04431453). REMDACTA is another trial utilizing remdesivir with tocilizumab combination for severe COVID-19 infections (NCT04409262). Remdesivir is also a part of the multicountry and multisite DISCOVERY trial by the Institut National de la Santé et de la Recherche Médicale (INSERM) Institute (France) which is enrolling COVID-19 patients with respiratory symptoms (NCT04315948). Phase Ia clinical trial of an inhaled version of remdesivir to treat COVID-19 patients in the outpatient setting is undergoing via Gillead Lifesciences.

**Conclusion**

COVID-19 infection is surging past territorial borders across the globe at a lightning pace. Hitherto, there has been no specific therapy for the infection. Hydroxychloroquine has been utilized in the initial days of the pandemic as a potential remedy. Remdesivir is an investigational antiviral drug with proven effectiveness against Ebola/MERS CoV viruses and has shown promising effects in in-vitro studies against COVID-19. After the initial success in the Compassionate use program, two large randomized trials (SIMPLE and ACTT1) both have shown significantly shortened recovery time and reduce mortality with the drug.
Remdesivir has been approved for emergency use in severely-ill patients in the United States, India, South Korea, and Japan based on contemporary clinical data. In addition, various clinical trials are ongoing to generate more data on the safety and efficacy of remdesivir for COVID-19. Remdesivir has definitely emerged as a valuable weapon for managing COVID-19 infection.

Implication for a family physician
The COVID-19 pandemic has led to a dramatic loss of human life worldwide and presents an unprecedented challenge to the entire globe. It is difficult to differentiate symptoms of COVID-19 and influenza-like illnesses by family physicians and medical officers on the first outdoor visit. Every physician should know the management of COVID-19 pneumonia according to the severity of the disease. Family physicians are generally the first contact of any type of illness including COVID-19. Hence, they should be aware of all types of management available for COVID-19. Remdesivir is the only available drug that consistently showed benefit in the management of moderate to severe COVID-19. This article is about a complete overview of remdesivir and a guide to a primary physician on when and how to use remdesivir.

Highlights
1. Coronavirus disease is by far the largest pandemic of the century. Within a short span of 6 months, it has spread to over 200 countries of the world.
2. Remdesivir (GS5734) is an antiviral nucleotide analog prodrug.
3. The United States Food and drug administration (US FDA) has also granted emergency use approval of the drug for moderate to severe COVID-19 in hospitalized patients.
4. Co-administration of remdesivir is not recommended with chloroquine or hydroxychloroquine.

Table 2: Guideline recommendations on Remdesivir use in COVID-19

| Guidelines                                                                 | Recommendation                                                                                                                                                                                                 |
|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Government of India (MOHFW) ministry of health and family welfare[27]      | Remdesivir may be considered in COVID-19 patients with moderate disease (patients on oxygen), 200 mg IV on day 1 followed by 100 mg IV daily for 5 days. Recommend that the remdesivir drugs not be administered as treatment or prophylaxis for COVID-19, outside of the context of clinical trials: |
| WHO[26]                                                                   | Remdesivir for treatment of COVID-19 in hospitalized patients with SpO₂ ≤94% on room air or those who require supplemental oxygen. The guideline recommends remdesivir for treatment of COVID-19 in patients who are on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) (BI). |
| NIH/CDC[27]                                                               | Remdesivir in severe COVID-19 patients, the guideline favors remdesivir over no antiviral treatment. In patients with severe COVID-19 who are receiving supplemental oxygen but not on mechanical ventilation or ECMO, 5 days of remdesivir therapy suggested instead of 10 days. |
| Infectious Diseases Society of America (IDSA) Management Guidelines[28]   |                                                                                                                                                                                                              |

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Corona virus update (Live)- Worldometer. 2nd February 2021. Available from: http://www.worldometer.info/coronavirus-/COVID 19 coronavirus pandemic. [Last accessed on 2021 Feb 02].
2. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA 2020;323:1824-36.
3. Brown AJ, Won JJ, Graham RL, Dinnon KH 3rd, Sims AC, Feng JY, et al. Broad spectrum antiviral emdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res 2019;169:104541.
4. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.
5. WHO Director-General’s opening remarks at the media briefing on COVID-19- WHO Newsletter. 13th April 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19. [Last accessed on 2020 Apr 13].
6. Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of Ebola virus disease therapeutics. New Engl J Med 2019;381:2293-303.
7. Shehan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination of lopinavir, ritonavir and interferon beta against MERS-CoV. Nat Commun 2020;11:222.
8. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.
9. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020;382:2327-36.
10. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:1569-78.
11. Goldman JD, Lye DSB, Hui DS, Marks KM, Bruno R, Montenegro R, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020;383:1827-37.
12. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. 2020. doi:10.1056/NEJMoa2007764.
13. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19—Final Report. N Engl J Med 2020;383:1813-26.
14. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al.; ACTT-2 Study Group Members. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021;384:795-807. doi: 10.1056/NEJMoa2031994.
15. WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, SathiyaMoorthy V, Abdool Karim Q, et al. Repurposed antiviral drugs for Covid-19:Interim WHO solidarity trial results. N Engl J Med 2021;384:497-511.
16. Sun D. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit. AAPS J 2020;22:77.
17. Whittington MD, Campbell JD. Alternative Pricing Models for Remdesivir and Other Potential Treatments for COVID-19: Institute of clinical and economic review (ICER). Available from: https://icer-review.org/wp-content/uploads/2020/05/ICER-COVID_Initia l_Abst ract_05012020-3pdf. [Last accessed on 2020 Jun 30].
18. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med 2020;383:517-25.
19. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020;323:2493-502.
20. Bajpai J, Pradhan A, Singh A, Kant S. Hydroxychloroquine and COVID-19-A narrative review. Indian J Tuberc 2020;67:S147-54.
21. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19: World Health Organization. 4th July 2020. Available from: https://www.who.int/newsroom/detail/WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for covid-19. [Last accessed on 2020 Jul 05].
22. Updates of COVID-19 in Japan: Ministry of Health, Labour and Welfare, Tokyo, Japan. 18th May, 2020. Available from: https://www.mhlw.go.jp/content/10900000/000631469pdf. [Last accessed on 2020 Jun 25].
23. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. 1st May 2020. Available from: https://www.fda.gov/news & events/newswire/press announcements/Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. [Last accessed on 2020 Jun 25].
24. Porecha M. COVID-19 treatment—DCGI approves Remdesivir for restricted emergency use-The Hindu: Business line, New Delhi, 2nd June 2020. Available from: https://www.thehindubusinessline.com/news/covid-19-treatment‑dcgi‑approves‑remdesivir‑for‑restricted‑emergency‑use/article31733556.ece. [Last accessed on 2020 Jun 25].
25. Clinical management protocol: COVID-19-Government of India, Ministry of Health and Family Welfare, Directorate General of Health Services (EMR Division). Version 4. 27th June 2020. Available from: https://www.mohfw.gov.in/pdf/clinical management protocol for COVID19.pdf. [Last accessed on 2020 Jun 30].
26. Clinical Management of COVID 19 interim guidance. World Health Organisation. 27th May 2020. Available from: https://www.who.int/emergencies/diseases/novel‑coronavirus‑2019/situation‑reports. [Last accessed on 2020 Jun 25].
27. COVID 19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 25th June 2020. National Institute of Health. Available from: https://www.covid19treatmentguidelines.nih.gov. [Last accessed on 2020 Jun 29].
28. Alhazzani W, Moller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020;46:854-87.